A Dose Regimen-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of Oradoxel Monotherapy in Subjects With Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 18 May 2017
At a glance
- Drugs Docetaxel (Primary) ; HM 30181A (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Athenex
- 12 May 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Apr 2019.
- 12 May 2017 Status changed from not yet recruiting to recruiting.
- 17 Nov 2016 New trial record